LILRB2 and cancer: We demonstrated that oligomeric cystatin C enhances the immunosuppressive activity of myeloid cells by engaging LILRB2/5 inhibitory receptors, thereby suppressing T-cell function and promoting cancer progression (Supplementary Fig. 11).